A61K 51/1042
Against t-cell receptor -cd3 complex
Official title: {against T-cell receptor (TcR)-CD3 complex}
A61K51/1042 (Against t-cell receptor -cd3 complex) appears on 12 US grants and 19 published applications in this corpus.
Search patents in A61K- Granted patents
- 12
- Published applications
- 19
- Assignees
- 18
- Inventors
- 59
- Latest grant
- 5 Aug 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 0 | 0 |
| 2003 | 1 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 1 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 0 |
| 2017 | 0 | 0 |
| 2018 | 0 | 5 |
| 2019 | 0 | 2 |
| 2020 | 1 | 3 |
| 2021 | 3 | 0 |
| 2022 | 1 | 2 |
| 2023 | 1 | 1 |
| 2024 | 2 | 1 |
| 2025 | 1 | 3 |
| 2026 | 0 | 1 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion5 Aug 2025US 12,377,143 B2Chugai Seiyaku Kabushiki Kaisha
- Use of bispecific antigen-binding molecules that bind MUC16 and CD3 in combination with 4-1BB co-stimulation17 Sep 2024US 12,091,460 B2Regeneron Pharmaceuticals, Inc.
- Feeder cell and method for growing gamma delta T cells by using same3 Sep 2024US 12,077,779 B2The Catholic University of Korea Industry-Academic Cooperation Foundation
- Multispecific antibodies that target HIV GP120 and CD37 Mar 2023US 11,597,759 B2Gilead Sciences, Inc.
- Multiple antigen binding molecular fusion, pharmaceutical composition, method for identifying linear epitope, and method for preparing multiple antigen binding molecular fusion2 Aug 2022US 11,400,157 B2Chugai Seiyaku Kabushiki Kaisha
- Anti-her2/cd3 bispecific antibody specifically activated in tumor microenvironment3 Sep 2026US 2026/0258127 A1Ying Mai De Medical Technology (Guangdong) Co., Ltd.
- Cd3 targeting antibodies and uses thereof6 Nov 2025US 2025/0340637 A1Abpro Corporation
- Agents for treatment of endometriosis and other benign gynecological neoplasms24 Jul 2025US 2025/0235567 A1UniversitäT ZüRich
- Use of bispecific antigen-binding molecules that bind muc16 and cd3 in combination with 4-1bb co-stimulation6 Feb 2025US 2025/0042999 A1Regeneron Pharmaceuticals, Inc.
- Therapeutic antibodies27 Jun 2024US 2024/0209086 A1Petmedix Ltd
Most cited
By later US patents
- Monoclonal antibody therapy18US 4,731,244 AOrtho Pharmaceutical Corporation · 1988
- Anti-ROR1 antibodies8US 11,155,615 B2Eureka Therapeutics, Inc. · 2021
- Alpha or beta emitters attached to fragments in radioimmunotherapy6US 6,667,024 B1Center for Molecular Medicine and Immunology · 2003
- Drug-conjugated bi-specific antigen-binding constructs4US 11,147,886 B2Zymeworks Inc. · 2021
- Multispecific antibodies that target HIV GP120 and CD32US 10,882,907 B2Gilead Sciences, Inc. · 2021